Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.2 USD | +4.69% | +1.94% | -14.43% |
10/05 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
08/05 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.43% | 1.13B | |
+39.30% | 50.93B | |
-0.24% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.03% | 26.02B | |
-22.32% | 18.9B | |
+8.66% | 13.21B | |
+24.56% | 12.17B | |
+29.10% | 12.16B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- SVB Securities Adjusts Price Target on Mirum Pharmaceuticals to $39 From $50, Maintains Outperform Rating